Immunogenicity and safety of PNEUMOVAX® II manufactured by a new process in older adults

Human Vaccines

Volumn 5, Issue 9, 2009, Pages 608-613

  Mair, Stuart ^a   Fiquet, Anne ^b   Meghlaoui, Gilles ^b   Thomas, Stephane ^b   Ledesma, Emilio ^b  

^a Inveresk Clinical Research   (United Kingdom)

^b SANOFI PASTEUR   (France)

Author keywords

Adult; Invasive pneumococcal disease; Pneumococcus; Polysaccharide; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; PNEUMOVAX II; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASTHENIA; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALE; PAIN; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; VACCINE PRODUCTION;

EID: 73649118818     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.9228     Document Type: Article

References (25)

1. Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors and clinical features. Semin Respir Crit Care Med 2005; 26:563-74.
2. Fedson DH, Musher DM. Pneumococcal polysaccharide vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia, PA: WB Saunders 2004.
3. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004; 113:701-7.
4. Sinaniotis CA, Sinaniotis AC. Community-acquired pneumonia in children. Curr Opin Pulm Med 2005; 11:218-25.
5. Connolly M, Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. Epidemiol Infect 1999; 122:41-9.
6. nd edition. St. Louis, MO: Mosby 2004; 251-65.
7. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, et al. Bacterial meningitis in the United States in 1995. New Engl J Med 1997; 337:970-6.
8. Sleeman K, Knox K, George R, Miller E, Waight P, Griffiths D, et al. Invasive pneumococcal disease in England and Wales: Vaccination implications. J Infect Dis 2001; 183:239-46.
9. Gwaltney JMJ. Acute community-acquired pneumonia. Clin Infect Dis 1996; 23:1209-23.
10. Block SL. Causative pathogens, antibiotic resistance and therapeutic consideration in acute otitis media. Pediatr Infect Dis 1997; 16:449-56.
11. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008; 7:1.
12. Johnson D, Stillwell MG, Fritsche TR, Jones RN. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 2006; 56:69-74.
13. Bruinsma N, Kristinsson KG, Bronzwaer S, Schrijnemakers P, Degener J, Tiemersma E, et al. Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe. J Antimicrob Chemother 2004; 54:1045-50.
14. Kyaw MH, Jones IG, Campbell H. Prevalence of penicillin non-susceptible invasive pneumococcal disease in the elderly in Scotland, 1992-99. Scand J Infect Dis 2002; 34:559-63.
15. Mooney JD, Weir A, McMenamin J, Ritchie LD, Macfarlane TV, Simpson CR, et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis 2008; 8:53.
16. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New Engl J Med 2003; 348:1737-46.
17. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368:1495-502.
18. Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007; 167:1938-43.
19. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30:100-21.
20. George RC, Johnson AP, Speller DC, Efstratiou A, Broughton K, Patel BC. Serogroups/types and antibiotic resistance of referred isolates of Streptococcus pneumoniae: 1993 to 1995. Commun Dis Rep Rev 1997; 7:66-73.
21. Marchese A, Tonoli E, Balisteri G, Debbia E, Schito GC. Antibiotic susceptibility patterns and serotypes of antibiotic resistant and/or invasive Streptococcus pneumoniae strains circulating in Italy. Microb Drug Resist 2000; 6:163-70.
22. Smith AJ, Jefferies J, Clarke SC, Dowson C, Edwards GF, Mitchell TJ. Distribution of epidemic antibiotic-resistant pneumococcal clones in Scottish pneumococcal isolates analysed by multilocus sequence typing. Microbiology 2006; 152:361-5.
23. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: Implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 2000; 30:122-40.
24. Marchese RD, Jain NT, Antonello J, Mallette L, Butterfield-Gerson KL, Raab J, et al. Enzyme-linked immunosorbent assay for measuring antibodies to pneumococcal polysaccharides for the PNEUMOVAX 23 vaccine: Assay operating characteristics and correlation to the WHO international assay. Clin Vacc Immunol 2006; 13:905-12.
25. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend Rep 1997; 46:1-28.